secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0000950170-24-121103
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR reports Q3 net loss $85.9M; CASGEVY now approved in Switzerland and Canada
--------------------------------------------------------------------------------

- Net loss $85.9M in Q3 2024 vs $112.2M loss in Q3 2023; cash and securities $1.935B as of Sept 30.
- CASGEVY approved for SCD and TDT in Switzerland and Canada; 45 ATCs activated globally.
- Approximately 40 patients have had cell collections across all regions as of mid-October.
- CTX112 Phase 1 data to be presented at ASH 2024: 67% ORR, 44% CRR in lymphoma patients.
- R&D expenses $82.2M (down from $90.7M); collaboration expense net $11.2M (down from $23.4M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017024121103/0000950170-24-121103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017024121103/crsp-20241105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-121103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer